Patent ID: 8097593
Filing Date: 2012-01-17
Classification: A61P,C07F,C07H

Abstract:
1. A method of stimulating the immune system of a subject comprising administering to a subject having cancer (i) an immunogen and; (ii) an immunostimulatory amount of a compound having the structure (I) wherein at least one of R wherein X, X wherein Y4 is a spacer selected from the group consisting of —O—, —S—, and —NH—, wherein, at least one of Y wherein each monovalent phosphate equivalent is, independently, (a) —R′—C(O)OH, where R′ is a substituted or unsubstituted alkyl group of 1-4 carbons, or (b) selected independently from the group consisting of —OB(OH)OR, —OP(O)(OH)OR, —OS(O)(O)(OH)OR, and —OP(═O)(OH)—O—P(═O)(OH)OR, where R is hydrogen, or a substituted or unsubstituted alkyl group of 1-4 carbons, and if R is a substituted alkyl group, the substitutions are —OH or —N wherein R wherein the glycosidic linkage is α or β; or an immunostimulatory amount of a compound having the structure (II) wherein at least one of R wherein Y4 is a spacer selected from the group consisting of —O—, —S—, and —NH—, and wherein, at least one of Y wherein the following limitations apply to both (I) and (II) above: Y R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 11 , R 12 and R 13 are independently hydrogen, a moiety which with the commonly numbered Y group forms monovalent phosphate equivalent as previously defined, or a strongly lipophilic group selected from the group consisting of (i)-(viii) above, the strongly lipophilic groups of said compound collectively provide at least two major carbon chains, and the major carbon chains of said strongly lipophilic groups collectively provide at least 30 carbon atoms; or which compound is a pharmaceutically acceptable salt of (I) or (II).